Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA-SCAD
2024-516039-28-00Phase 4Authorised
- Sponsor
- Sociedad Española de Cardiología
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of metoprolol, bisoprolol, carvedilol, atenolol, propranolol and 4 more in spontaneous coronary artery dissection (SCAD), acute coronary syndrome (ACS), myocardial infarction (MI) and 2 more (3 arms), sponsored by Sociedad Española de Cardiología. Primary endpoint: Composite major adverse cardiovascular events at 1 year. Planned start Jul 2024; status: authorised.
02
Drugs
metoprololbisoprololcarvedilolatenololpropranolol
03
Conditions
spontaneous coronary artery dissection (SCAD)acute coronary syndrome (ACS)myocardial infarction (MI)strokeheart failure (HF)
Beyond the preview
Go deeper on 2024-516039-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516039-28-00.